Functional Cognitive Disorder. Other symptoms and signs involving cognitive functions and awareness
Conditions
Interventions
Intervention 1: Participants in this group will receive Bupropion ER 150 mg. The drug is manufactured by Abidi and is available in oral tablet form. The daily dose is one tablet (150 mg) taken orally,
Sponsors
Artesh University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 18 to 50 years of age Cognitive complaints (Memory, attention, concentration) Individuals must meet diagnostic criteria for functional cognitive disorder (FCD) based on clinical assessment by a psychiatrist or neurologist FCD Criteria: Clinical Features: Compared to dementia, people with FCD generally present alone, are self-aware of their memory and cognitive decline, remember and give examples of times when they had memory problems with high accuracy, and their memory problems are not constant and are more noticeable at certain times (especially in stressful situations). Clinical features and diagnostic tests do not point to another neurological or psychiatric disease (such as Alzheimer's, depression, and ADHD)
Exclusion criteria
Exclusion criteria: Contraindications for bupropion (sensitivity to the drug, history of seizures, as well as diseases that predispose a person to seizures, such as head trauma, brain tumors, structural and vascular problems in the brain, and suffering from anorexia or bulimia) Concomitant use of MAOIs such as (phenelzine selegiline, tranylcypromine) Taking methylene blue or linezolid Taking antidepressants (TCAs, SSRIs, SNRIs) Cardiovascular diseases Pregnancy Breastfeeding Intending to get pregnant in the next 2 months History of glaucoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Cognitive Function Score (MoCA). Timepoint: At the beginning of the study (before the intervention) and 8 weeks after starting the drug. Method of measurement: Montreal Cognitive Assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reported side effects. Timepoint: 8 weeks after starting the drug. Method of measurement: Side effects checklist.;Beck Depression Score. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after starting the drug. Method of measurement: Beck Depression Inventory.;Hamilton Anxiety Score. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after starting the drug. Method of measurement: Hamilton Anxiety Scale.;Wechsler Memory Test Score. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after starting the drug. Method of measurement: Wechsler Memory Test.;EMQ-R score. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after starting the drug. Method of measurement: Everyday Memory Questionnaire-Revised.;Stroop test score. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after starting the drug. Method of measurement: Stroop test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Alikhani
Artesh University of Medical Sciences
Outcome results
None listed